Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

New Drug Combo Shows Promise Against Aggressive Leukemia in Landmark Study

A novel drug combination targeting LSD1 and GSK3 shows promise in treating acute myeloid leukemia by promoting cell differentiation and reducing tumor growth.

28 Apr 2025

DNA Aptamers Offer Precision Attack Against Leukemia Stem Cells

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

4 Apr 2025

OGT Delivers Superior MRD Detection Capabilities with New SureSeq Myeloid MRD Panel

Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low frequency measurable residual disease (MRD)-associated biomarkers in acute myeloid leukemia (AML).

23 Jan 2025

Single-Cell Analysis Sheds Light on Leukemia Cell Heterogeneity

Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

26 Nov 2024

Study Links Extracellular Vesicles to Blood Vessel Damage in Cancer

A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.

29 Oct 2024

Scientists Discover How AML Cells Use P-Bodies to Sustain Growth

An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth.

22 Aug 2024

The Protein STAT3 Helps the Immune System Fight Leukemia

Study at the Karl Landsteiner University of Health Sciences uncovers unknown interaction between leukemic cells and immune cells. Potential biomarkers for future immunotherapies found.

From Karl Landsteiner University of Health Sciences 17 Jul 2024

Syntekabio to Unveil Novel Biologics Platform at 20th Annual PEGS Boston Summit

Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform. The event is being held May 13-17, 2024 at the Omni Hotel at the Seaport, Boston, MA.

11 May 2024

Study Elucidates How Mutant NPM1 Protein Drives Leukemia by Activating Autophagy System

In a recent study, scientists led by Professor Stefan Müller from Goethe University's Institute of Biochemistry II investigated a specific form of blood cancer known as acute myeloid leukemia, or AML.

5 Dec 2023

Wilmot Researchers Uncover a "Genomic Tug of War" That Influences Decitabine's Effectiveness

Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant over time.

17 Nov 2023

Mechanisms of MCL-1 Inhibitor-Induced MCL-1 Protein Upregulation and Induction of Apoptosis

A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability."

29 Jun 2023

Cell Fate Conversion Plays Crucial Role in Cancer Research

Researchers from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin and the Centre for Genomic Regulation (CRG) in Barcelona have discovered how cells speed changes to their identity known as “cell fate conversion.”

28 Jun 2023

CloneTracer Reveals a Differentiation Landscape of Acute Myeloid Leukemia

Researchers have developed a new method to distinguish between cancerous and healthy stem cells and progenitor cells from samples of patients with acute myeloid leukemia (AML), a disease driven by malignant blood stem cells that have historically been difficult to identify.

25 Apr 2023

New Epigenetic Vulnerability Of Acute Myeloid Leukemia Revealed

Acute myeloid leukemia (AML) is an aggressive blood cancer that causes uncontrolled accumulation of white blood cells. Because of the poor outcomes of this disease, researchers across the globe have been on the hunt for new ways to treat AML, while preserving normal blood development.

10 Apr 2023

Previously unknown telomere and cancer connection to the immune system revealed

Johns Hopkins Medicine scientists say their 20-year study of more than 200 people with premature aging syndromes caused by abnormally short telomeres, or shortened repetitive DNA sequences at the ends of chromosomes, may upend long-held scientific dogma and settle conflicting studies about how and whether short telomeres contribute to cancer risk.

31 Mar 2023

Potential therapeutic can synergize with existing drugs to effectively destroy leukemia cells

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

9 Mar 2023

Study pinpoints a splicing deregulation that causes therapeutic vulnerability in pediatric AML

Pediatric acute myeloid leukemia or pAML is a childhood blood cancer, one that has proved confounding to clinicians and researchers, with a high relapse rate and relatively few identified genetic mutations (compared to the adult version) that might explain its cause.

8 Mar 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Novel combination therapy shows promise in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.

8 Feb 2023

Revealing the functional significance of DDX41 in great detail

The DDX41 gene encodes the nuclear enzyme DEAD-box-type RNA helicase. Hematopoietic malignancies are caused by DDX41 mutations. However, the mechanism behind the development of this malignancy remains unknown.

21 Nov 2022